We are live on
!
Find out more
B
Bailard Portfolio holdings
AUM
$4.35B
1-Year Est. Return
23.57%
This Fund
S&P 500
This Quarter
Est. Return
+11.33%
1 Year Est. Return
+23.57%
3 Year Est. Return
+74.84%
5 Year Est. Return
+96.64%
10 Year Est. Return
+374.16%
AUM
$4.29B
AUM Growth
+$416M
(+11%)
Cap. Flow
+$61.9M
Cap. Flow
% of AUM
1.44%
Top 10 Holdings %
Top 10 Hldgs %
28.63%
Holding
861
New
126
Increased
252
Reduced
282
Closed
107
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Emerging Markets ETF
EEM
|
+$74.1M |
| 2 |
iShares Short-Term National Muni Bond ETF
SUB
|
+$15M |
| 3 |
JPMorgan Municipal ETF
JMUB
|
+$12.2M |
| 4 |
iShares California Muni Bond ETF
CMF
|
+$10.7M |
| 5 |
Broadcom
AVGO
|
+$10.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Total Bond Market
BND
|
+$78.2M |
| 2 |
JPMorgan Ultra-Short Municipal Income ETF
JMST
|
+$18.1M |
| 3 |
iShares iBonds Dec 2026 Term Treasury ETF
IBTG
|
+$12.2M |
| 4 |
State Street SPDR Portfolio Short Term Treasury ETF
SPTS
|
+$5.93M |
| 5 |
Invesco S&P 500 Equal Weight ETF
RSP
|
+$5.55M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23% |
| 2 | Financials | 8.01% |
| 3 | Healthcare | 6.98% |
| 4 | Communication Services | 5.95% |
| 5 | Consumer Discretionary | 4.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
726
Portillo's
PTLO
$310M
| $193K | ﹤0.01% |
+16,500
| New | +$190K |
|
727
Fulcrum Therapeutics
FULC
$249M
| $185K | ﹤0.01% |
+26,881
| New | +$144K |
|
728
Organogenesis Holdings
ORGO
$309M
| $157K | ﹤0.01% |
42,913
| – | – |
|
|
ITOS
729
DELISTED
iTeos Therapeutics
ITOS
| $152K | ﹤0.01% |
+15,200
| New | +$122K |
|
730
Greenlight Captial
GLRE
$538M
| $147K | ﹤0.01% |
10,200
| – | – |
|
731
iShares Global Clean Energy ETF
ICLN
$2.47B
| $146K | ﹤0.01% |
11,099
| – | – |
|
|
ATXS
732
DELISTED
Astria Therapeutics
ATXS
| $142K | ﹤0.01% |
+26,500
| New | +$128K |
|
733
SurgePays
SURG
$6.37M
| $141K | ﹤0.01% |
45,075
-405
| -0.9% | -$1.12K |
|
734
LXP Industrial Trust
LXP
$3.53B
| $134K | ﹤0.01% |
3,256
-12
| -0.4% | -$494 |
|
735
Vanda Pharmaceuticals
VNDA
$322M
| $123K | ﹤0.01% |
26,100
+3,631
| +16% | +$15.9K |
|
|
UHG
736
DELISTED
United Homes Group
UHG
| $116K | ﹤0.01% |
+40,084
| New | +$104K |
|
737
Ideal Power
IPWR
$67.8M
| $102K | ﹤0.01% |
22,540
-202
| -0.9% | -$977 |
|
738
Monte Rosa Therapeutics
GLUE
$1.99B
| $101K | ﹤0.01% |
+22,500
| New | +$100K |
|
739
Aurinia Pharmaceuticals
AUPH
$1.97B
| $99.1K | ﹤0.01% |
+11,700
| New | +$93.8K |
|
740
Agilon Health
AGL
$1.74B
| $97K | ﹤0.01% |
1,686
-15
| -0.9% | -$1.2K |
|
|
DFTX
741
Definium Therapeutics
DFTX
$5.81B
| $94.8K | ﹤0.01% |
14,600
| – | – |
|
742
Protara Therapeutics
TARA
$229M
| $90.2K | ﹤0.01% |
29,769
| – | – |
|
|
VTYX
743
DELISTED
Ventyx Biosciences
VTYX
| $88.4K | ﹤0.01% |
+41,300
| New | +$66.7K |
|
|
LFT
744
Lument Finance Trust
LFT
$43.3M
| $87.3K | ﹤0.01% |
39,525
+21,474
| +119% | +$54.1K |
|
|
NHS
745
Neuberger High Yield Strategies Fund Inc
NHS
$252M
| $82.2K | ﹤0.01% |
10,839
| – | – |
|
746
SIGA Technologies
SIGA
$224M
| $77.6K | ﹤0.01% |
+11,900
| New | +$71.4K |
|
747
Editas Medicine
EDIT
$419M
| $74.5K | ﹤0.01% |
33,875
| – | – |
|
748
Aegon
AEG
$13.4B
| $74.4K | ﹤0.01% |
10,283
| – | – |
|
749
Ampco-Pittsburgh
AP
$170M
| $59K | ﹤0.01% |
19,934
+7,434
| +59% | +$19.3K |
|
750
Smart Sand
SND
$205M
| $49.8K | ﹤0.01% |
+24,800
| New | +$50.2K |
|
Similar funds
EC
SFM
NHC
EQF
NEI
MYIA
Bailard's Q2 2025 Portfolio in Review
As of Q2 2025, Bailard held 861 positions worth $4.29B, up 11% from $3.87B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Bailard's Q2 2025 filing shows 126 new, 252 increased, 282 reduced and 107 closed positions. Its largest new stake was iShares ESG Advanced MSCI EAFE ETF: 70,823 shares worth $5.27M. The largest sale was Vanguard Total Bond Market, an estimated $78.2M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 21% a quarter earlier, followed by Financials and Healthcare.
- Bailard's largest Q2 2025 buy was iShares ESG Advanced MSCI EAFE ETF: 70,823 shares worth $5.27M.
- Bailard added most to iShares MSCI Emerging Markets ETF in Q2 2025, an estimated $74.1M increase.
- Bailard's biggest Q2 2025 reduction was JPMorgan Ultra-Short Municipal Income ETF, cutting an estimated $18.1M.
- Bailard fully exited Vanguard Total Bond Market in Q2 2025, selling an estimated $78.2M.
- Bailard's ten largest holdings make up 29% of its $4.29B portfolio in Q2 2025.
- Bailard opened 126 new positions and closed 107 in Q2 2025.
- Bailard's portfolio value rose 11% quarter-over-quarter to $4.29B.
Based on Bailard's 13F filing for Q2 2025, filed 8 Aug 2025.